Navigation Links
The Lancet Diabetes & Endocrinology: Large clinical trials to evaluate risks of testosterone treatment urgently needed
Date:4/27/2014

Physicians do not have sufficient information from clinical trials to understand the risks associated with the prescription of testosterone in older men, according to a Comment in The Lancet Diabetes & Endocrinology, written by Professor Stephanie Page, of the University of Washington and Harborview Medical Center, Seattle, USA.

While the benefits of testosterone therapy in younger men with a deficiency of the hormone are well established, testosterone is now widely prescribed to older men, particularly in the USA.

Existing studies have produced conflicting findings over whether the prescription of testosterone is associated with increased cardiovascular risk in older men, and ongoing studies are unlikely to adequately address this question, meaning that even if an appropriately powered trial were to start today, reliable safety data are at least a decade away.

According to Professor Page, "In an era when millions of men are using testosterone every day, support is urgently needed from both the public and medical communities to fund an appropriate clinical study to assess the risks and benefits of testosterone treatment in older men. There is a danger that funding and regulatory agencies will overinterpret the evidence from existing and ongoing observational studies, and conclude that larger and longer clinical trials are unnecessary and unwarranted. This conclusion would do men's health a disservice."*

"Testosterone is a billion dollar industry, probably fuelled partly by direct to consumer advertising and some degree of overprescription," Professor Page adds. "Physicians need to discuss with their patients that we simply do not fully understand the risks associated with testosterone use in older men, and use conservative treatment guidelines such as those provided by the Endocrine Society to guide therapeutic decisions."*


'/>"/>

Contact: Stephanie Page
page@u.washington.edu
The Lancet
Source:Eurekalert

Page: 1

Related medicine news :

1. Premier global health journal, The Lancet, releases series on universal health coverage
2. Indias patent laws under pressure: The Lancet special report
3. Lancet Oncology: Long-term side-effects of targeted therapies in pediatric cancer patients
4. 1-year results of ADAPT-DES trial published in The Lancet
5. More Babies are Oversized as Maternal Obesity Rate Rises, Lancet Report Says
6. The Lancet: China halves tuberculosis prevalence in just 20 years
7. The Lancet journals: World TB Day media alert
8. How a cancer drug leads to diabetes
9. Heart failure patients with diabetes may benefit from higher glucose levels
10. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
11. Mouse Study Hints at New Path for Diabetes Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... An inventor from Cana, Va., wanted to fulfill the need ... park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. ... set up in a matter of minutes, or even seconds. The SAFETY STRAP FOR ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... will become Quality Insights beginning January 1, 2017. The name change aligns ... commitment to measuring and improving health care quality. , “We are very proud ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
(Date:12/8/2016)... 2016 KEY FINDINGS ... Patient warming and cooling ... during surgeries, lowering the risks of neurological disorders post cardiac ... The patient warming systems can be segmented into convective warming ... turn reduce the stay at hospitals thus, lowering the healthcare ...
(Date:12/8/2016)... Inc. (NYSE: DPLO) has been recognized by the Detroit Free ... To learn more about Diplomat,s career opportunities, visit ... ... ... a research firm specializing in organizational health and workplace improvement. The ...
Breaking Medicine Technology: